Obesity Market Could See Two Near-Term Entrants; Pfizer Says Combo Is Key
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Obesity market could see two near-term entrants, Pfizer says. Sanofi-Aventis will submit Acomplia in early Q2 2005; Regeneron’s Axokine is in Phase III. Pfizer is looking at combination therapy for metabolic syndrome, including Caduet and atorvastatin/torcetrapib. Firms are focusing on cardiovascular benefits